Pfizer, already flush with cash, will reap $16B from selling shares in GSK consumer health spinoff

By combining its consumer health business with GSK's in 2019, Pfizer made clear its plan to focus on innovative medicines and vaccines. Now, in exiting the consumer market, the New York pharma is collecting a huge cash windfall.